Breaking News

Biogen Idec Names Chief Strategy Officer

April 10, 2014

Koppel to lead corporate strategy and portfolio management

Adam M. Koppel, M.D., Ph.D., has been appointed senior vice president and chief strategy officer at Biogen Idec, effective May 15, 2014. Dr. Koppel will be responsible for leading corporate strategy and portfolio management, reporting to George Scangos, Ph.D., chief executive officer. He will also serve as member of the management team.
Dr. Koppel will join the company from Brookside Capital, the public equity affiliate of Bain Capital, where he served as a managing director since 2009. Prior to Brookside Capital, he was an associate principal of the McKinsey Healthcare Practice.
“With his experience as a physician, scientist and executive, Adam will be invaluable to Biogen Idec as we grow in size and complexity, bringing a unique set of capabilities to bolster our position at the intersection of medicine, science and economics,” said Dr. Scangos. “Adam is a respected biotechnology investor and industry leader, and we are thrilled to have his insight and vision to help guide our company and management team.”
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks